Terns Pharmaceuticals (TERN) Enterprise Value (2020 - 2023)
Historic Enterprise Value for Terns Pharmaceuticals (TERN) over the last 4 years, with Q3 2023 value amounting to -$266.6 million.
- Terns Pharmaceuticals' Enterprise Value fell 4234.91% to -$266.6 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$266.6 million, marking a year-over-year decrease of 4234.91%. This contributed to the annual value of -$283.1 million for FY2022, which is 7056.91% down from last year.
- Per Terns Pharmaceuticals' latest filing, its Enterprise Value stood at -$266.6 million for Q3 2023, which was down 4234.91% from -$285.6 million recorded in Q2 2023.
- Terns Pharmaceuticals' 5-year Enterprise Value high stood at -$11.7 million for Q1 2020, and its period low was -$297.5 million during Q1 2023.
- For the 4-year period, Terns Pharmaceuticals' Enterprise Value averaged around -$163.7 million, with its median value being -$177.2 million (2021).
- As far as peak fluctuations go, Terns Pharmaceuticals' Enterprise Value tumbled by 157220.42% in 2021, and later skyrocketed by 2446.13% in 2022.
- Terns Pharmaceuticals' Enterprise Value (Quarter) stood at -$74.9 million in 2020, then crashed by 121.74% to -$166.0 million in 2021, then plummeted by 70.57% to -$283.1 million in 2022, then grew by 5.83% to -$266.6 million in 2023.
- Its last three reported values are -$266.6 million in Q3 2023, -$285.6 million for Q2 2023, and -$297.5 million during Q1 2023.